RecruitingNCT00807482

Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease

Diagnostic and Clinical Characterization of Patients With Unusual Genetic Disorders of the Airways


Sponsor

University of North Carolina, Chapel Hill

Enrollment

1,800 participants

Start Date

Jan 1, 2004

Study Type

OBSERVATIONAL

Conditions

Summary

The overall short-term goals of this project include the following: 1) identify the genes that are key to the function of respiratory cilia to protect the normal lung; and 2) the effects of genetic mutations that adversely affect ciliary function and cause primary ciliary dyskinesia (PCD), which results in life-shortening lung disease. The long-term goal of this project is to develop better understanding of the underlying genetic variability that adversely modifies ciliary function, and predisposes to common airway diseases, such as asthma and chronic obstructive pulmonary disease.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with kartagener syndrome. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00807482


Related Trials